Compare AbCellera Biologics Inc (ABCL) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Materials Select Sector SPDR Fund — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Materials Select Sector SPDR Fund trades at $50.3. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABCL | XLB | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $53.62 |
52-Week Low | $2.78 | $42.23 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $51.98, down slightly by 0.06% today. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF, which provides broad exposure to the U.S. materials sector, lacks disclosed fundamental ratios like P/E and P/S in the provided data. Recent news highlights sector interest, with family offices investing $4.8 billion in materials as of May 23, 2026 (Barron's).
The outlook for XLB is supported by sector rotation into materials amid geopolitical shifts and earnings growth potential, but risks include sensitivity to macroeconomic factors and inflation. Analyst sentiment is mixed, with some viewing valuations as less compelling after recent gains. The ETF's performance will hinge on broader industrial and economic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
